MIRM Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -13.15% compared to Mirum Pharmaceuticals's net margin of -1633.49%. Mirum Pharmaceuticals's return on equity of -33.5% beat Editas Medicine's return on equity of -139.77%.

Mirum Pharmaceuticals has a consensus price target of $68.60, signalling upside risk potential of 35.31%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 57.71%. Given that Editas Medicine has higher upside potential than Mirum Pharmaceuticals, analysts believe Editas Medicine is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 0.951, which suggesting that the stock is 4.935% less volatile than S&P 500. In comparison Editas Medicine has a beta of 2.100, suggesting its more volatile than the S&P 500 by 109.954%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $111.6M, which are larger than Editas Medicine quarterly revenues of $4.7M. Mirum Pharmaceuticals's net income of -$14.7M is higher than Editas Medicine's net income of -$76.1M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 7.04x versus 4.93x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of -13.15% compared to Mirum Pharmaceuticals's net margin of 40.52%. Mirum Pharmaceuticals's return on equity of -33.5% beat Krystal Biotech's return on equity of 13.91%.

Mirum Pharmaceuticals has a consensus price target of $68.60, signalling upside risk potential of 35.31%. On the other hand Krystal Biotech has an analysts' consensus of $205.20 which suggests that it could grow by 57.82%. Given that Krystal Biotech has higher upside potential than Mirum Pharmaceuticals, analysts believe Krystal Biotech is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 0.951, which suggesting that the stock is 4.935% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.7%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $111.6M, which are larger than Krystal Biotech quarterly revenues of $88.2M. Mirum Pharmaceuticals's net income of -$14.7M is lower than Krystal Biotech's net income of $35.7M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 31.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 7.04x versus 11.64x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -13.15% compared to Mirum Pharmaceuticals's net margin of -907.48%. Mirum Pharmaceuticals's return on equity of -33.5% beat Moderna's return on equity of -29.23%.

Mirum Pharmaceuticals has a consensus price target of $68.60, signalling upside risk potential of 35.31%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 86.27%. Given that Moderna has higher upside potential than Mirum Pharmaceuticals, analysts believe Moderna is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 0.951, which suggesting that the stock is 4.935% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $111.6M, which are larger than Moderna quarterly revenues of $107M. Mirum Pharmaceuticals's net income of -$14.7M is higher than Moderna's net income of -$971M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 7.04x versus 3.17x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -13.15% compared to Mirum Pharmaceuticals's net margin of -151.35%. Mirum Pharmaceuticals's return on equity of -33.5% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

Mirum Pharmaceuticals has a consensus price target of $68.60, signalling upside risk potential of 35.31%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $83.42 which suggests that it could grow by 34.61%. Given that Mirum Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Mirum Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 0.951, which suggesting that the stock is 4.935% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.301, suggesting its more volatile than the S&P 500 by 130.127%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $111.6M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Mirum Pharmaceuticals's net income of -$14.7M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 7.04x versus 27.95x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.